Sun Pharmaceutical Industries has received US FDA approval for Eloxatin, oxdiplatin for injection and generic version of Imitrex, sumatriptan succinate tablets. The company will share 180 days exclusivity for generic version of Eloxatin.
These oxdiplatin injections, 50 mg and 100 mg packed in single use vials, are therapeutically equivalent to Eloxatin injections from sanofi-aventis. Oxdiplatin injections have annual sales of approximately US$2.3 billion in the US and it is used on anticancer treatment of colon and rectal cancer.
The sumatriptan succinate tablets, 25 mg, 50 mg and 100mg are therapeutically equivalent to Imitrex tablets from GlaxoSmithKline. These tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.